Drug Shortage Report for TRIESENCE
Report ID | 83368 |
Drug Identification Number | 02368676 |
Brand name | TRIESENCE |
Common or Proper name | TRIESENCE 1ML SUSP X12 |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | TRIAMCINOLONE ACETONIDE |
Strength(s) | 40MG |
Dosage form(s) | SUSPENSION |
Route of administration | INTRAVITREAL |
Packaging size | 12 |
ATC code | S01BA |
ATC description | ANTIINFLAMMATORY AGENTS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2019-06-03 |
Actual start date | 2019-05-27 |
Estimated end date | 2020-08-31 |
Actual end date | 2020-09-02 |
Shortage status | Resolved |
Updated date | 2020-09-08 |
Company comments | Production constraints limit product availability. Inventory being periodically released based on stock received. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.